Sight Sciences Inc. Common Stock Earnings Recaps
Q3 2025
Nov 7, 2025
Sight Sciences delivered a robust Q3 2025 with revenues of $19.9 million, driven by strong adoption of its interventional glaucoma technologies and exciting advancements in its dry eye treatment segment.
Key takeaways
- Raised full-year 2025 revenue guidance to $76 million to $78 million, reflecting positive momentum.
- Achieved key reimbursements in the TearCare segment with new fee schedules in place for over 10 million Medicare-covered lives.
- Experienced sequential growth in Surgical Glaucoma revenue, indicating effective operational execution and market demand.
- Targeted commercialization efforts underway for TearCare, with a focus on expanding market access and customer advocacy among 6,500 potential adopters.
Q2 2025
Aug 8, 2025
Sight Sciences reported solid Q2 2025 results, achieving $19.6 million in revenue and raising its full-year revenue guidance to $72 million to $76 million due to robust growth in its Surgical Glaucoma segment.
Key takeaways
- Surgical Glaucoma revenue increased by 12% sequentially, although it was down 5% year-over-year, highlighting resilience amidst evolving market conditions.
- The company achieved record high ordering accounts, up 6% sequentially, signaling effective client reengagement and new account acquisition.
- Strong early traction and positive surgeon feedback from the recently launched OMNIEdge technology are expected to bolster future utilization and growth.
- Maintained focus on operational excellence with high gross margins and diligent expense management, confirming commitment to long-term shareholder value.
- Continued efforts to secure positive reimbursement coverage for TearCare, aligning with broader market opportunities in minimally invasive glaucoma treatments.